| Year |
Citation |
Score |
| 2020 |
Chacko A, Moss RB. Manifestations of pulmonary aspergillosis in pediatrics. Current Opinion in Pediatrics. 32: 389-394. PMID 32371841 DOI: 10.1097/Mop.0000000000000898 |
0.386 |
|
| 2020 |
Robinson TE, Goris ML, Moss RB, Tian L, Kan P, Yilma M, McCoy KS, Newman B, de Jong PA, Long FR, Brody AS, Behrje R, Yates DP, Cornfield DN. Mucus plugging, air trapping, and bronchiectasis are important outcome measures in assessing progressive childhood cystic fibrosis lung disease. Pediatric Pulmonology. PMID 31962004 DOI: 10.1002/Ppul.24646 |
0.351 |
|
| 2020 |
Nichols DP, Moss RB. Early Aspergillosis in Cystic Fibrosis and Air Trapping: Guilt by Association? American Journal of Respiratory and Critical Care Medicine. PMID 31904998 DOI: 10.1164/Rccm.201912-2309Ed |
0.326 |
|
| 2018 |
Kim J, Farahmand M, Dunn C, Milla CE, Horii RI, Thomas EAC, Moss RB, Wine JJ. Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults. Scientific Reports. 8: 16233. PMID 30389955 DOI: 10.1038/S41598-018-34308-8 |
0.325 |
|
| 2018 |
Tracy MC, Moss RB. The myriad challenges of respiratory fungal infection in cystic fibrosis. Pediatric Pulmonology. PMID 29992775 DOI: 10.1002/Ppul.24126 |
0.422 |
|
| 2018 |
Forrest OA, Chopyk DM, Gernez Y, Brown MR, Conrad CK, Moss RB, Tangpricha V, Peng L, Tirouvanziam R. Resistin is elevated in cystic fibrosis sputum and correlates negatively with lung function. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 29937317 DOI: 10.1016/J.Jcf.2018.05.018 |
0.395 |
|
| 2018 |
Burgener EB, Moss RB. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis. Current Opinion in Pediatrics. PMID 29538046 DOI: 10.1097/Mop.0000000000000627 |
0.394 |
|
| 2017 |
Wagener JS, Millar SJ, Mayer-Hamblett N, Sawicki GS, McKone EF, Goss CH, Konstan MW, Morgan WJ, Pasta DJ, Moss RB. Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 29100868 DOI: 10.1016/J.Jcf.2017.10.003 |
0.378 |
|
| 2017 |
Sabino R, Carolino E, Moss RB, Banaei N, Verissimo C, Stevens DA. Susceptibility of Candida albicans from Cystic Fibrosis Patients. Mycopathologia. PMID 28421452 DOI: 10.1007/S11046-017-0133-9 |
0.382 |
|
| 2017 |
Sawicki G, Konstan M, McKone E, Moss R, Lubarsky B, Suthoff E, Millar S, Pasta D, Mayer-Hamblett N, Goss C, Morgan W. P255 Rate of lung function decline in patients with cystic fibrosis (cf) having a residual function gene mutation Thorax. 72. DOI: 10.1136/Thoraxjnl-2017-210983.397 |
0.374 |
|
| 2017 |
Konstan M, McKone E, Moss R, Lubarsky B, Rubin J, Millar S, Pasta D, Mayer-Hamblett N, Goss C, Morgan W, Sawicki G. 54 Relationship between rate of percent predicted FEV1 (ppFEV1) decline and baseline and acute change in ppFEV1 in patients (pts) with cystic fibrosis (CF) treated with lumacaftor/ivacaftor (LUM/IVA) Journal of Cystic Fibrosis. 16: S78. DOI: 10.1016/S1569-1993(17)30419-8 |
0.374 |
|
| 2017 |
Robinson T, Goris M, Moss R, Tian L, Kan P, Yilma M, McCoy K, Newman B, de Jong P, Long F, Brody A, Behrje R, Yates D, Cornfield D. EPS4.3 Differential sensitivity of outcome measures that assess progression of mild CF lung disease in school age children Journal of Cystic Fibrosis. 16: S44-S45. DOI: 10.1016/S1569-1993(17)30304-1 |
0.316 |
|
| 2016 |
Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, Huang X, Lubarsky B, Rubin J, Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan W, Sawicki GS. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. The Lancet. Respiratory Medicine. PMID 28011037 DOI: 10.1016/S2213-2600(16)30427-1 |
0.319 |
|
| 2016 |
Nazik H, Moss RB, Karna V, Clemons KV, Banaei N, Cohen K, Choudhary V, Stevens DA. Are Cystic Fibrosis Aspergillus fumigatus Isolates Different? Intermicrobial Interactions with Pseudomonas. Mycopathologia. PMID 27822731 DOI: 10.1007/S11046-016-0087-3 |
0.422 |
|
| 2016 |
Gernez Y, Waters J, Tirouvanziam R, Herzenberg L, Moss R. Basophil activation test determination of CD63 combined with CD203c is not superior to CD203c alone in identifying allergic bronchopulmonary aspergillosis in cystic fibrosis. The Journal of Allergy and Clinical Immunology. PMID 27215492 DOI: 10.1016/J.Jaci.2016.04.002 |
0.313 |
|
| 2016 |
Moss RB. Treating allergic bronchopulmonary aspergillosis: the way forward. The European Respiratory Journal. 47: 385-7. PMID 26828049 DOI: 10.1183/13993003.01816-2015 |
0.336 |
|
| 2016 |
Stevens DA, Moss RB, Hernandez C, Clemons KV, Martinez M. EFFECT OF MEDIA MODIFIED TO MIMIC CYSTIC FIBROSIS SPUTUM ON THE SUSCEPTIBILITY OF ASPERGILLUS FUMIGATUS, AND THE FREQUENCY OF RESISTANCE AT ONE CENTER. Antimicrobial Agents and Chemotherapy. PMID 26810647 DOI: 10.1128/Aac.02649-15 |
0.401 |
|
| 2016 |
Sullivan J, Accurso F, Marigowda G, Beusmans J, Geho D, Zhang E, Moss R, Waltz D. WS04.2 Improvement in inflammatory biomarkers in patients (pts) with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation treated with lumacaftor (LUM) and ivacaftor (IVA) Journal of Cystic Fibrosis. 15: S6. DOI: 10.1016/S1569-1993(16)30079-0 |
0.405 |
|
| 2016 |
Gernez Y, Waters J, Dunn CE, Davies Z, Everson C, Tirouvanziam R, Herzenberg L, Moss RB. Modulatory Effects of Aspergillus Colonization and Abpa on Blood and Sputum Granulocytes in CF The Journal of Allergy and Clinical Immunology. 137. DOI: 10.1016/J.Jaci.2015.12.094 |
0.342 |
|
| 2015 |
Gernez Y, Walters J, Mirković B, Lavelle GM, Colleen DE, Davies ZA, Everson C, Tirouvanziam R, Silver E, Wallenstein S, Chotirmall SH, McElvaney NG, Herzenberg LA, Moss RB. Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis. The European Respiratory Journal. PMID 26585435 DOI: 10.1183/13993003.01068-2015 |
0.449 |
|
| 2015 |
Mirković B, Lavelle GM, Azim AA, Helma K, Gargoum FS, Molloy K, Gernez Y, Dunne K, Renwick J, Murphy P, Moss RB, Greene CM, Gunaratnam C, Chotirmall SH, McElvaney NG. The basophil surface marker CD203c identifies Aspergillus species sensitization in patients with cystic fibrosis. The Journal of Allergy and Clinical Immunology. PMID 26388311 DOI: 10.1016/J.Jaci.2015.07.045 |
0.411 |
|
| 2015 |
Ferreira JA, Penner JC, Moss RB, Haagensen JA, Clemons KV, Spormann AM, Nazik H, Cohen K, Banaei N, Carolino E, Stevens DA. Inhibition of Aspergillus fumigatus and Its Biofilm by Pseudomonas aeruginosa Is Dependent on the Source, Phenotype and Growth Conditions of the Bacterium. Plos One. 10: e0134692. PMID 26252384 DOI: 10.1371/Journal.Pone.0134692 |
0.327 |
|
| 2015 |
Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. The Lancet. Respiratory Medicine. 3: 524-33. PMID 26070913 DOI: 10.1016/S2213-2600(15)00201-5 |
0.364 |
|
| 2015 |
Milla CE, Moss RB. Recent advances in cystic fibrosis. Current Opinion in Pediatrics. 27: 317-24. PMID 25888148 DOI: 10.1097/Mop.0000000000000226 |
0.378 |
|
| 2015 |
Moss RB. Fungi in cystic fibrosis and non-cystic fibrosis bronchiectasis. Seminars in Respiratory and Critical Care Medicine. 36: 207-16. PMID 25826588 DOI: 10.1055/S-0035-1546750 |
0.438 |
|
| 2015 |
Sabino R, Ferreira JA, Moss RB, Valente J, Veríssimo C, Carolino E, Clemons KV, Everson C, Banaei N, Penner J, Stevens DA. Molecular epidemiology of Aspergillus collected from cystic fibrosis patients. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 14: 474-81. PMID 25459562 DOI: 10.1016/J.Jcf.2014.10.005 |
0.445 |
|
| 2015 |
Conrad C, Lymp J, Thompson V, Dunn C, Davies Z, Chatfield B, Nichols D, Clancy J, Vender R, Egan ME, Quittell L, Michelson P, Antony V, Spahr J, Rubenstein RC, ... Moss RB, et al. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 14: 219-27. PMID 25228446 DOI: 10.1016/J.Jcf.2014.08.008 |
0.374 |
|
| 2014 |
Char JE, Wolfe MH, Cho HJ, Park IH, Jeong JH, Frisbee E, Dunn C, Davies Z, Milla C, Moss RB, Thomas EA, Wine JJ. A little CFTR goes a long way: CFTR-dependent sweat secretion from G551D and R117H-5T cystic fibrosis subjects taking ivacaftor. Plos One. 9: e88564. PMID 24520399 DOI: 10.1371/Journal.Pone.0088564 |
0.315 |
|
| 2014 |
Moss RB. Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis. The European Respiratory Journal. 43: 1487-500. PMID 24311776 DOI: 10.1183/09031936.00139513 |
0.344 |
|
| 2014 |
Moss R, Flume P, Elborn J, Cooke J, Rowe S, McColley S, Rubenstein R, Higgins M. WS23.6 Ivacaftor treatment in patients with cystic fibrosis who have an R117H-CFTR mutation, the KONDUCT study Journal of Cystic Fibrosis. 13: S44. DOI: 10.1016/S1569-1993(14)60137-5 |
0.378 |
|
| 2014 |
Gernez Y, Waters J, Dunn C, Davies Z, Tirouvanziam R, Everson C, Tamaresis J, Herzenberg L, Moss RB. Basophil Activation Is a Reliable Biomarker Of Allergic Bronchopulmonary Aspergillosis (ABPA) In CF: One Year Results Of a Longitudinal Cohort Study Journal of Allergy and Clinical Immunology. 133: AB58. DOI: 10.1016/J.Jaci.2013.12.229 |
0.36 |
|
| 2013 |
Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JFGM, Guleria R, Moss R, Denning DW. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria Clinical & Experimental Allergy. 43: 850-873. PMID 23889240 DOI: 10.1111/Cea.12141 |
0.369 |
|
| 2013 |
Moss RB. Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. The Journal of Pediatrics. 162: 676-80. PMID 23290508 DOI: 10.1016/J.Jpeds.2012.11.034 |
0.41 |
|
| 2013 |
Moss RB, Mistry SJ, Konstan MW, Pilewski JM, Kerem E, Tal-Singer R, Lazaar AL. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 12: 241-8. PMID 22995323 DOI: 10.1016/J.Jcf.2012.08.016 |
0.359 |
|
| 2013 |
Ruddy J, Emerson J, Moss R, Genatossio A, McNamara S, Burns JL, Anderson G, Rosenfeld M. Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 26: 69-75. PMID 22620494 DOI: 10.1089/Jamp.2011.0942 |
0.316 |
|
| 2013 |
Moss RB, Waters J, Dunn C, Davies Z, Everson C, Tirouvanziam R, Tameresis J, Herzenberg LA, Gernez Y. WS22.1 Basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis (ABPA) in CF: Interim results of a longitudinal cohort study Journal of Cystic Fibrosis. 12. DOI: 10.1016/S1569-1993(13)60138-1 |
0.378 |
|
| 2012 |
Ratjen F, Durham T, Navratil T, Schaberg A, Accurso FJ, Wainwright C, Barnes M, Moss RB. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 11: 539-49. PMID 22682898 DOI: 10.1016/J.Jcf.2012.05.003 |
0.409 |
|
| 2012 |
Gernez Y, Dunn CE, Everson C, Mitsunaga E, Gudiputi L, Krasinska K, Davies ZA, Herzenberg LA, Tirouvanziam R, Moss RB. Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by aspergillus allergens. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 11: 502-10. PMID 22608296 DOI: 10.1016/J.Jcf.2012.04.008 |
0.449 |
|
| 2012 |
Knutsen AP, Bush RK, Demain JG, Denning DW, Dixit A, Fairs A, Greenberger PA, Kariuki B, Kita H, Kurup VP, Moss RB, Niven RM, Pashley CH, Slavin RG, Vijay HM, et al. Fungi and allergic lower respiratory tract diseases. The Journal of Allergy and Clinical Immunology. 129: 280-91; quiz 292-3. PMID 22284927 DOI: 10.1016/J.Jaci.2011.12.970 |
0.341 |
|
| 2012 |
Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, De Boeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, ... ... Moss RB, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 67: 12-8. PMID 21825083 DOI: 10.1136/Thoraxjnl-2011-200393 |
0.372 |
|
| 2012 |
Gernez Y, Everson C, Dunn CE, Fernandez-Becker N, Gudiputi L, Davies ZA, Herzenberg LA, Tirouvanziam R, Moss RB. WS9.7 Modulatory effects of Aspergillus colonization and ABPA on blood and sputum eosinophils and neutrophils in CF Journal of Cystic Fibrosis. 11. DOI: 10.1016/S1569-1993(12)60066-6 |
0.351 |
|
| 2012 |
Gernez Y, Everson C, Mitsunaga E, Dunn C, Herzenberg L, Tirouvanziam R, Moss R. Specific Induction Of CD203c Expression In Blood Basophils Discriminates Between CF patients With Aspergillus Colonization And Those With CF-ABPA The Journal of Allergy and Clinical Immunology. 129. DOI: 10.1016/J.Jaci.2011.12.466 |
0.391 |
|
| 2011 |
Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, DÅ™evÃnek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. The New England Journal of Medicine. 365: 1663-72. PMID 22047557 DOI: 10.1056/Nejmoa1105185 |
0.421 |
|
| 2011 |
Accurso FJ, Moss RB, Wilmott RW, Anbar RD, Schaberg AE, Durham TA, Ramsey BW. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. American Journal of Respiratory and Critical Care Medicine. 183: 627-34. PMID 21169471 DOI: 10.1164/Rccm.201008-1267Oc |
0.395 |
|
| 2011 |
Gernez Y, Tirouvanziam R, Dunn CE, Everson C, Davis ZA, Herzenberg LA, Moss RB. 184* Basophil CD203c as a potential clinically relevant biomarker in cystic fibrosis and allergic bronchopulmonary aspergillosis Journal of Cystic Fibrosis. 10. DOI: 10.1016/S1569-1993(11)60200-2 |
0.366 |
|
| 2010 |
Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. The New England Journal of Medicine. 363: 1991-2003. PMID 21083385 DOI: 10.1056/Nejmoa0909825 |
0.392 |
|
| 2010 |
Moss RB. Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis. Current Opinion in Pulmonary Medicine. 16: 598-603. PMID 20720494 DOI: 10.1097/Mcp.0B013E32833E24A6 |
0.345 |
|
| 2010 |
Yuan N, Kane P, Shelton K, Matel J, Becker BC, Moss RB. Safety, tolerability, and efficacy of high-frequency chest wall oscillation in pediatric patients with cerebral palsy and neuromuscular diseases: an exploratory randomized controlled trial. Journal of Child Neurology. 25: 815-21. PMID 20357238 DOI: 10.1177/0883073809350223 |
0.314 |
|
| 2010 |
Navratil T, Evans C, Schaberg A, Johnson F, Durham T, Ren C, Ratjen F, Moss R, Accurso F. Aerosol and pharmacokinetic properties of denufosol support its use for early intervention in CF lung disease Journal of Cystic Fibrosis. 9: S21. DOI: 10.1016/S1569-1993(10)60079-3 |
0.336 |
|
| 2010 |
Moss RB, Schaberg A, Deans C, Tian W, Smiley L, Herje N, Durham T, Accurso FJ. Denufosol improves lung function in adolescent CF patients Journal of Cystic Fibrosis. 9. DOI: 10.1016/S1569-1993(10)60077-X |
0.352 |
|
| 2009 |
Robinson TE, Leung AN, Chen X, Moss RB, Emond MJ. Cystic fibrosis HRCT scores correlate strongly with Pseudomonas infection. Pediatric Pulmonology. 44: 1107-17. PMID 19824046 DOI: 10.1002/Ppul.21107 |
0.394 |
|
| 2009 |
Makam M, Diaz D, Laval J, Gernez Y, Conrad CK, Dunn CE, Davies ZA, Moss RB, Herzenberg LA, Herzenberg LA, Tirouvanziam R. Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs. Proceedings of the National Academy of Sciences of the United States of America. 106: 5779-83. PMID 19293384 DOI: 10.1073/Pnas.0813410106 |
0.391 |
|
| 2009 |
Moss RB. Infection, inflammation, and the downward spiral of cystic fibrosis lung disease. The Journal of Pediatrics. 154: 162-3. PMID 19150671 DOI: 10.1016/J.Jpeds.2008.09.042 |
0.37 |
|
| 2009 |
Banner KH, De Jonge H, Elborn S, Growcott E, Gulbins E, Konstan M, Moss R, Poll C, Randell SH, Rossi AG, Thomas L, Waltz D. Highlights of a workshop to discuss targeting inflammation in cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 8: 1-8. PMID 19022708 DOI: 10.1016/J.Jcf.2008.10.002 |
0.313 |
|
| 2009 |
Accurso F, Rowe S, Durie P, Konstan M, Dunitz J, Hornick D, Sagel S, Boyle M, Uluer A, Moss R, Ramsey B, Freedman S, Dong Q, Zha J, Stone A, et al. Final results of a 14- and 28-day study of VX-770 in subjects with CF Journal of Cystic Fibrosis. 8: S25. DOI: 10.1016/S1569-1993(09)60101-6 |
0.317 |
|
| 2008 |
Tirouvanziam R, Gernez Y, Conrad CK, Moss RB, Schrijver I, Dunn CE, Davies ZA, Herzenberg LA, Herzenberg LA. Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways. Proceedings of the National Academy of Sciences of the United States of America. 105: 4335-9. PMID 18334635 DOI: 10.1073/Pnas.0712386105 |
0.358 |
|
| 2008 |
Moss RB. Management of allergic aspergillosis Current Fungal Infection Reports. 2: 87-93. DOI: 10.1007/S12281-008-0014-2 |
0.354 |
|
| 2008 |
Moss RB. Management of allergic aspergillosis Current Allergy and Asthma Reports. 8: 433-439. DOI: 10.1007/S11882-008-0083-X |
0.359 |
|
| 2007 |
Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP, Spencer LT, Pilewski J, Waltz DA, Dorkin HL, Ferkol T, Pian M, Ramsey B, Carter BJ, Martin DB, et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Human Gene Therapy. 18: 726-32. PMID 17685853 DOI: 10.1089/Hum.2007.022 |
0.414 |
|
| 2007 |
Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatric Pulmonology. 42: 610-23. PMID 17534969 DOI: 10.1002/Ppul.20625 |
0.335 |
|
| 2007 |
Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson R, Zeitlin P, Berclaz P, Moss R, Knowles MR, Oster RA, Mayer-Hamblett N, Ramsey B. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. American Journal of Respiratory Cell and Molecular Biology. 37: 57-66. PMID 17347447 DOI: 10.1165/Rcmb.2006-0173Oc |
0.39 |
|
| 2006 |
Moss RB. Critique of trials in allergic bronchopulmonary aspergillosis and fungal allergy. Medical Mycology. 44: S269-S272. PMID 30408913 DOI: 10.1080/13693780600835757 |
0.377 |
|
| 2006 |
Kurup VP, Knutsen AP, Moss RB, Bansal NK. Specific antibodies to recombinant allergens of Aspergillus fumigatus in cystic fibrosis patients with ABPA. Clinical and Molecular Allergy : Cma. 4: 11. PMID 16859543 DOI: 10.1186/1476-7961-4-11 |
0.422 |
|
| 2006 |
Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proceedings of the National Academy of Sciences of the United States of America. 103: 4628-33. PMID 16537378 DOI: 10.1073/Pnas.0511304103 |
0.428 |
|
| 2006 |
Gernez Y, Conrad C, Moss R, Herzenberg L, Tirouvanziam R. 115 - Single-cell phosphoepitope profiling in live blood and sputum neutrophils brings insights into cystic fibrosis inflammatory pathophysiology Revue Des Maladies Respiratoires. 23: 573-573. DOI: 10.1016/S0761-8425(06)71943-X |
0.314 |
|
| 2005 |
Robinson TE, Goris ML, Zhu HJ, Chen X, Bhise P, Sheikh F, Moss RB. Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis. Chest. 128: 2327-35. PMID 16236891 DOI: 10.1378/Chest.128.4.2327 |
0.362 |
|
| 2005 |
Xiao W, Hsu YP, Ishizaka A, Kirikae T, Moss RB. Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. Chest. 128: 2316-26. PMID 16236890 DOI: 10.1378/Chest.128.4.2316 |
0.393 |
|
| 2005 |
Moss RB. Pathophysiology and immunology of allergic bronchopulmonary aspergillosis. Medical Mycology. 43: S203-6. PMID 16110813 DOI: 10.1080/13693780500052255 |
0.377 |
|
| 2005 |
Schrijver I, Karnsakul W, Limwongse C, Ramalingam S, Sankaran R, Gardner P, Moss R. Novel contributions to the Asian CFTR mutation spectrum: Genotype and phenotype in Thai patients with cystic fibrosis. American Journal of Medical Genetics. Part A. 133: 103-5. PMID 15744829 DOI: 10.1002/Ajmg.A.30472 |
0.357 |
|
| 2005 |
Moss RB, Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, Gibson RL, Anderson P, Retsch-Bogart G, Nasr SZ, Noth I, Waltz D, Zeitlin P, Ramsey B, Starko K. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatric Pulmonology. 39: 209-18. PMID 15573395 DOI: 10.1002/Ppul.20152 |
0.364 |
|
| 2004 |
Bonnel AS, Song SM, Kesavarju K, Newaskar M, Paxton CJ, Bloch DA, Moss RB, Robinson TE. Quantitative air-trapping analysis in children with mild cystic fibrosis lung disease. Pediatric Pulmonology. 38: 396-405. PMID 15390349 DOI: 10.1002/Ppul.20091 |
0.351 |
|
| 2004 |
Moss RB. Lymphocytes in cystic fibrosis lung disease: a tale of two immunities. Clinical and Experimental Immunology. 135: 358-60. PMID 15008966 DOI: 10.1111/J.1365-2249.2003.02389.X |
0.459 |
|
| 2004 |
Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, Milla C, Brody AS, Clancy JP, Ramsey B, Hamblett N, Heald AE. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest. 125: 509-21. PMID 14769732 DOI: 10.1378/Chest.125.2.509 |
0.397 |
|
| 2004 |
Dorsaneo D, Borowitz D, Sharp J, Moss R. Allergic Bronchopulmonary Aspergillosis with Normal Serum IgE in a Child with Cystic Fibrosis Pediatric Asthma, Allergy & Immunology. 17: 146-150. DOI: 10.1089/0883187041269922 |
0.339 |
|
| 2004 |
Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, Denning DW, Crameri R, Brody AS, Light M, Skov M, Maish W, Mastella G. Erratum: Allergic bronchopulmonary aspergillosis in cystic fibrosis - State of the art: Cystic Fibrosis Foundation Consensus Conference (Clinical Infectious Diseases (2003) 37:Suppl. 3 (S225-64)) Clinical Infectious Diseases. 38. DOI: 10.1086/381363 |
0.391 |
|
| 2003 |
Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, Denning DW, Crameri R, Brody AS, Light M, Skov M, Maish W, Mastella G. Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 37: S225-64. PMID 12975753 DOI: 10.1086/376525 |
0.336 |
|
| 2003 |
Robinson TE, Leung AN, Northway WH, Blankenberg FG, Chan FP, Bloch DA, Holmes TH, Moss RB. Composite spirometric-computed tomography outcome measure in early cystic fibrosis lung disease. American Journal of Respiratory and Critical Care Medicine. 168: 588-93. PMID 12746252 DOI: 10.1164/Rccm.200209-1093Oc |
0.334 |
|
| 2003 |
Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 167: 841-9. PMID 12480612 DOI: 10.1164/Rccm.200208-855Oc |
0.348 |
|
| 2002 |
Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Batson EP, Dimiceli S, Brown BW, Desch JK, Norbash AM, Conrad CK, Guggino WB, Flotte TR, Wine JJ, Carter BJ, Reynolds TC, ... Moss RB, et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Human Gene Therapy. 13: 1349-59. PMID 12162817 DOI: 10.1089/104303402760128577 |
0.363 |
|
| 2002 |
Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest. 121: 55-63. PMID 11796432 DOI: 10.1378/Chest.121.1.55 |
0.368 |
|
| 2001 |
Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR, McNamara SC, Gibson RL, Ramsey BW, Carter BJ, Reynolds TC. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Human Gene Therapy. 12: 1907-16. PMID 11589832 DOI: 10.1089/104303401753153956 |
0.376 |
|
| 2001 |
Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest. 120: 107S-113S. PMID 11555564 DOI: 10.1378/Chest.120.3_Suppl.107S |
0.41 |
|
| 2001 |
Robinson TE, Leung AN, Northway WH, Blankenberg FG, Bloch DA, Oehlert JW, Al-Dabbagh H, Hubli S, Moss RB. Spirometer-triggered high-resolution computed tomography and pulmonary function measurements during an acute exacerbation in patients with cystic fibrosis. The Journal of Pediatrics. 138: 553-9. PMID 11295720 DOI: 10.1067/Mpd.2001.111820 |
0.397 |
|
| 2001 |
Wine JJ, Kuo E, Hurlock G, Moss RB. Comprehensive mutation screening in a cystic fibrosis center. Pediatrics. 107: 280-6. PMID 11158459 DOI: 10.1542/Peds.107.2.280 |
0.305 |
|
| 2000 |
Moss RB, Hsu YP, Olds L. Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Clinical and Experimental Immunology. 120: 518-25. PMID 10844532 DOI: 10.1046/J.1365-2249.2000.01232.X |
0.306 |
|
| 1999 |
Wagner JA, Messner AH, Moran ML, Daifuku R, Kouyama K, Desch JK, Manley S, Norbash AM, Conrad CK, Friborg S, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, et al. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. The Laryngoscope. 109: 266-74. PMID 10890777 DOI: 10.1097/00005537-199902000-00017 |
0.385 |
|
| 1999 |
Wagner JA, Nepomuceno IB, Shah N, Messner AH, Moran ML, Norbash AM, Moss RB, Wine JJ, Gardner P. Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials in patients with antrostomies. The Journal of Gene Medicine. 1: 13-21. PMID 10738581 DOI: 10.1002/(SICI)1521-2254(199901/02)1:1<13::AID-JGM6>3.3.CO;2-7 |
0.44 |
|
| 1999 |
Illek B, Zhang L, Lewis NC, Moss RB, Dong JY, Fischer H. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. The American Journal of Physiology. 277: C833-9. PMID 10516113 DOI: 10.1152/Ajpcell.1999.277.4.C833 |
0.38 |
|
| 1999 |
Wagner JA, Vassilakis A, Yee K, Li M, Hurlock G, Krouse ME, Moss RB, Wine JJ. Two novel mutations in a cystic fibrosis patient of Chinese origin. Human Genetics. 104: 511-5. PMID 10453741 DOI: 10.1007/S004390050996 |
0.301 |
|
| 1999 |
Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Redding G, Rubio T, Williams-Warren J, Wilmott R, Wilson HD, Yogev R. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. The Journal of Pediatrics. 134: 413-21. PMID 10190914 DOI: 10.1016/S0022-3476(99)70197-6 |
0.304 |
|
| 1999 |
Nepomuceno IB, Esrig S, Moss RB. Allergic bronchopulmonary aspergillosis in cystic fibrosis: Role of atopy and response to itraconazole Chest. 115: 364-370. PMID 10027433 DOI: 10.1378/Chest.115.2.364 |
0.446 |
|
| 1999 |
Robinson TE, Leung AN, Moss RB, Blankenberg FG, Bloch DA, Oehlert JW, Al-Dabbagh H, Hubli S, Northway WH. Spirometer-Triggered High Resolution Computed Tomography (HRCT) of the Chest, Clinical Score, and Pulmonary Function Measurements in Cystic Fibrosis (CF) Patients before and after Treatment for a Pulmonary Exacerbation Pediatric Research. 45: 355A-355A. DOI: 10.1203/00006450-199904020-02108 |
0.41 |
|
| 1998 |
Wagner JA, Moran ML, Messner AH, Daifuku R, Conrad CK, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, Flotte TR, Gardner P. A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. Human Gene Therapy. 9: 889-909. PMID 9581911 DOI: 10.1089/Hum.1998.9.6-889 |
0.348 |
|
| 1998 |
Mickle JE, Macek M, Fulmer-Smentek SB, Egan MM, Schwiebert E, Guggino W, Moss R, Cutting GR. A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis. Human Molecular Genetics. 7: 729-35. PMID 9499426 DOI: 10.1093/Hmg/7.4.729 |
0.398 |
|
| 1997 |
Dosanjh AK, Elashoff D, Kawalek A, Moss RB, Esrig S. Activation of eosinophils in the airways of lung transplantation patients Chest. 112: 1180-1183. PMID 9367454 DOI: 10.1378/Chest.112.5.1180 |
0.327 |
|
| 1996 |
Moss RB, Bocian RC, Hsu YP, Dong YJ, Kemna M, Wei T, Gardner P. Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR) Clinical and Experimental Immunology. 106: 374-388. PMID 8918588 DOI: 10.1046/J.1365-2249.1996.D01-826.X |
0.375 |
|
| 1996 |
Wilmott RW, Amin RS, Colin AA, DeVault A, Dozor AJ, Eigen H, Johnson C, Lester LA, McCoy K, McKean LP, Moss R, Nash ML, Jue CP, Regelmann W, Stokes DC, et al. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. American Journal of Respiratory and Critical Care Medicine. 153: 1914-7. PMID 8665055 DOI: 10.1164/Ajrccm.153.6.8665055 |
0.408 |
|
| 1996 |
Wagner I, Moran M, Kouyama K, Moss R, Wine J, Gardner P. Clinical protocol: AAV-CFTR for the treatment of chronic sinusitis in CF patients. Clinical Pharmacology & Therapeutics. 59: 174-174. DOI: 10.1038/Sj.Clpt.1996.197 |
0.39 |
|
| 1995 |
Moss RB. Cystic fibrosis: Pathogenesis, pulmonary infection, and treatment Clinical Infectious Diseases. 21: 839-851. PMID 8645828 DOI: 10.1093/Clinids/21.4.839 |
0.412 |
|
| 1994 |
Bachrach LK, Loutit CW, Moss RB, Marcus R. Osteopenia in adults with cystic fibrosis The American Journal of Medicine. 96: 27-34. PMID 8304359 DOI: 10.1016/0002-9343(94)90112-0 |
0.312 |
|
| 1993 |
Cheung AT, Moss RB, Kurland G, Leong AB, Novick WJ. Chronic Pseudomonas aeruginosa endobronchitis in rhesus monkeys: II. A histopathologic analysis. Journal of Medical Primatology. 22: 257-62. PMID 8230177 DOI: 10.1111/J.1600-0684.1993.Tb00666.X |
0.364 |
|
| 1992 |
Moss RB, Carmack MA, Esrig S. Deficiency of IgG4 in children: association of isolated IgG4 deficiency with recurrent respiratory tract infection. The Journal of Pediatrics. 120: 16-21. PMID 1731015 DOI: 10.1016/S0022-3476(05)80590-6 |
0.342 |
|
| 1992 |
Cheung AT, Moss RB, Leong AB, Novick WJ. Chronic Pseudomonas aeruginosa endobronchitis in rhesus monkeys: I. Effects of pentoxifylline on neutrophil influx Journal of Medical Primatology. 21: 357-362. PMID 1307753 DOI: 10.1111/J.1600-0684.1992.Tb00604.X |
0.404 |
|
| 1991 |
Moss RB, McClelland E, Williams RR, Hilman BC, Rubio T, Adkinson NF. Evaluation of the immunologic cross-reactivity of aztreonam in patients with cystic fibrosis who are allergic to penicillin and/or cephalosporin antibiotics. Reviews of Infectious Diseases. 13: S598-607. PMID 2068466 DOI: 10.1093/Clinids/13.Supplement_7.S598 |
0.392 |
|
| 1991 |
Moss RB. Sensitization to aztreonam and cross-reactivity with other beta-lactam antibiotics in high-risk patients with cystic fibrosis The Journal of Allergy and Clinical Immunology. 87: 78-88. PMID 1991925 DOI: 10.1016/0091-6749(91)90215-A |
0.381 |
|
| 1991 |
Moss RB. Drug allergy in cystic fibrosis Clinical Reviews in Allergy. 9: 211-229. PMID 1884325 DOI: 10.1007/978-1-4612-0475-6_12 |
0.395 |
|
| 1990 |
Umetsu DT, Moss RB, King VV, Lewiston NJ. Sinus disease in patients with severe cystic fibrosis: relation to pulmonary exacerbation. Lancet (London, England). 335: 1077-8. PMID 1970379 DOI: 10.1016/0140-6736(90)92642-U |
0.41 |
|
| 1990 |
Van Wye JE, Collins MS, Baylor M, Pennington JE, Hsu YP, Sampanvejsopa V, Moss RB. Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis Pediatric Pulmonology. 9: 7-18. PMID 1697059 DOI: 10.1002/Ppul.1950090104 |
0.384 |
|
| 1989 |
Eichler I, Joris L, Hsu Y, Wye JV, Bram R, Moss R. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses. Journal of Clinical Investigation. 84: 1794-1804. PMID 2512330 DOI: 10.1172/Jci114364 |
0.393 |
|
| 1988 |
Reid MJ, Schwietz LA, Whisman BA, Moss RB. Mountain cedar pollinosis: can it occur in non-atopics? New England and Regional Allergy Proceedings. 9: 225-232. PMID 3412291 DOI: 10.2500/108854188779023450 |
0.323 |
|
| 1988 |
Moss RB. The role of IgG subclass antibodies in chronic infection: the case of cystic fibrosis New England and Regional Allergy Proceedings. 9: 57-61. PMID 3362109 DOI: 10.2500/108854188778984491 |
0.367 |
|
| 1988 |
Terr AI, Moss RB, Strober S. Effect of total lymphoid irradiation on IgE antibody responses in rheumatoid arthritis and systemic lupus erythematosus. The Journal of Allergy and Clinical Immunology. 80: 798-802. PMID 3320160 DOI: 10.1016/S0091-6749(87)80268-3 |
0.308 |
|
| 1988 |
Smith AL, Redding G, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Rubio T. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. The Journal of Pediatrics. 112: 547-54. PMID 3127569 DOI: 10.1016/S0022-3476(88)80165-3 |
0.361 |
|
| 1987 |
Moss RB. Hypergammaglobulinemia in cystic fibrosis. Role of Pseudomonas endobronchial infection. Chest. 91: 522-526. PMID 3829744 DOI: 10.1378/Chest.91.4.522 |
0.335 |
|
| 1987 |
Moss RB, Hsu YP, Kwasnicki JM, Sullivan MM, Reid MJ. Isotypic and antigenic restriction of the blocking antibody response to ryegrass pollen: Correlation of rye group I antigen-specific IgG1 with clinical response The Journal of Allergy and Clinical Immunology. 79: 387-398. PMID 3819220 DOI: 10.1016/0091-6749(87)90160-6 |
0.317 |
|
| 1987 |
Moss RB, Hsu YP, Van Eede PH, Van Leeuwen AM, Lewiston NJ, De Lange G. Altered antibody isotype in cystic fibrosis: impaired natural antibody response to polysaccharide antigens. Pediatric Research. 22: 708-13. PMID 3501565 DOI: 10.1203/00006450-198712000-00020 |
0.396 |
|
| 1987 |
Moss RB, Hsu YP, Lewiston NJ, Delange G. IMPAIRED NATURAL IgG2 ANTIBODY (AB) RESPONSE TO POLYSACCHARIDE ANTIGENS AND DECREASED Km(1)–A2m(2) ALLOTYPES IN CYSTIC FIBROSIS (CF) Pediatric Research. 21: 330A-330A. DOI: 10.1203/00006450-198704010-00978 |
0.416 |
|
| 1986 |
Moss RB, Hsu YP, Sullivan MM, Lewiston NJ. Altered antibody isotype in cystic fibrosis: possible role in opsonic deficiency. Pediatric Research. 20: 453-9. PMID 3714355 DOI: 10.1203/00006450-198605000-00015 |
0.403 |
|
| 1986 |
Moss RB, Hsu YP, Lewiston NJ, Curd JG, Milgrom H, Hart S, Dyer B, Larrick JW. Association of systemic immune complexes, complement activation, and antibodies to Pseudomonas aeruginosa lipopolysaccharide and exotoxin A with mortality in cystic fibrosis. The American Review of Respiratory Disease. 133: 648-52. PMID 3083745 DOI: 10.1164/Arrd.1986.133.4.648 |
0.408 |
|
| 1986 |
Sullivan MM, Moss RB, Hindi RD, Lewiston NJ. Supraventricular tachycardia in patients with cystic fibrosis. Chest. 90: 239-42. PMID 2426046 DOI: 10.1378/Chest.90.2.239 |
0.419 |
|
| 1985 |
BLESSINGMOORE J, RUBINSTEIN S, HINDI R, MOSS R, LEWISTON N, LEONG R, MACHTINGER S. 8 Once a day theophylline (uniphyl) for treatment of patients with asthma (AS) and cystic fibrosis(CF) Journal of Allergy and Clinical Immunology. 75: 106. DOI: 10.1016/0091-6749(85)90143-5 |
0.41 |
|
| 1984 |
Ortolani C, Pastorello E, Moss RB, Hsu Y, Restuccia M, Joppolo G, Miadonna A, Cornelli U, Halpern G, Zanussi C. Grass pollen immunotherapy: A single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis The Journal of Allergy and Clinical Immunology. 73: 283-290. PMID 6366027 DOI: 10.1016/S0091-6749(84)80021-4 |
0.335 |
|
| 1984 |
Moss RB, Babin S, Hsu YP, Blessing-Moore J, Lewiston NJ. Allergy to semisynthetic penicillins in cystic fibrosis. The Journal of Pediatrics. 104: 460-6. PMID 6323664 DOI: 10.1016/S0022-3476(84)81117-8 |
0.361 |
|
| 1982 |
Moss R, Hsu Y. Autoimmunity in cystic fibrosis: Evidence against polyclonal B cell activation The Journal of Allergy and Clinical Immunology. 69: 112. DOI: 10.1016/S0091-6749(62)80359-5 |
0.317 |
|
| 1981 |
Moss RB, Hsu YP, Lewiston NJ. 125I-Clq-binding and specific antibodies as indicators of pulmonary disease activity in cystic fibrosis. The Journal of Pediatrics. 99: 215-22. PMID 7252678 DOI: 10.1016/S0022-3476(81)80453-2 |
0.412 |
|
| 1980 |
Moss RB, Lewiston NJ. Immune complexes and humoral response to Pseudomonas aeruginosa in cystic fibrosis. The American Review of Respiratory Disease. 121: 23-9. PMID 6766286 DOI: 10.1164/Arrd.1980.121.1.23 |
0.423 |
|
| Show low-probability matches. |
